A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers
Purpose This study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), safety/tolerability, and cardiac safety of liposomal muramyl tripeptide phosphatidyl-ethanolamine [mifamurtide (L-MTP-PE)] in healthy adults. Methods L-MTP-PE 4 mg was administered intravenously over 30 min. Study participants were monitored from 24 h preinfusion until 72 h postinfusion. Blood samples were drawn over 0–72 h postdose to determine serum MTP-PE, interleukin (IL)-6, tumor necrosis factor (TNF)-α, and C-reactive protein (CRP) concentrations. Electrocardiograpic (ECG) data were collected via continuous Holter monitoring beginning 24 h predose through 24 h postdose. Changes from time-matched pretreatment baseline QTc and associated two-sided 90 % confidence intervals were calculated. Results Twenty-one participants received L-MTP-PE. Total serum MTP-PE declined rapidly with a terminal half-life of 2.05 ± 0.40 h. PK variability was low, with <30 % coefficient of variation in systemic exposure. Serum concentrations of IL-6, TNF-α, and CRP increased following L-MTP-PE infusion. Maximum observed increases in IL-6 and TNF-α occurred at 4 and 2 h, respectively, returning toward baseline by 8 h postdose. L-MTP-PE was generally well tolerated, with no adverse events greater than grade 3. Headache, chills, tachycardia, nausea, and pyrexia were the most frequent adverse events. L-MTP-PE infusion resulted in an increased heart rate without readily apparent QTc prolongation. Conclusions MTP-PE PK following L-MTP-PE administration were characterized by a short serum half-life and low variability. Increases in IL-6, TNF-α, and CRP and the safety profile were consistent with the immunomodulatory mechanism of action. No clinically significant effect of L-MTP-PE on cardiovascular repolarization was observed based on analysis of ECG QTc intervals..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2012 |
---|---|
Erschienen: |
2012 |
Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
---|---|
Enthalten in: |
European journal of clinical pharmacology - 68(2012), 10 vom: 30. März, Seite 1347-1355 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Venkatakrishnan, Karthik [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
---|
Anmerkungen: |
© Springer-Verlag 2012 |
---|
doi: |
10.1007/s00228-012-1262-1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR002578980 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR002578980 | ||
003 | DE-627 | ||
005 | 20230519124047.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201001s2012 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00228-012-1262-1 |2 doi | |
035 | |a (DE-627)SPR002578980 | ||
035 | |a (SPR)s00228-012-1262-1-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Venkatakrishnan, Karthik |e verfasserin |4 aut | |
245 | 1 | 2 | |a A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers |
264 | 1 | |c 2012 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Springer-Verlag 2012 | ||
520 | |a Purpose This study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), safety/tolerability, and cardiac safety of liposomal muramyl tripeptide phosphatidyl-ethanolamine [mifamurtide (L-MTP-PE)] in healthy adults. Methods L-MTP-PE 4 mg was administered intravenously over 30 min. Study participants were monitored from 24 h preinfusion until 72 h postinfusion. Blood samples were drawn over 0–72 h postdose to determine serum MTP-PE, interleukin (IL)-6, tumor necrosis factor (TNF)-α, and C-reactive protein (CRP) concentrations. Electrocardiograpic (ECG) data were collected via continuous Holter monitoring beginning 24 h predose through 24 h postdose. Changes from time-matched pretreatment baseline QTc and associated two-sided 90 % confidence intervals were calculated. Results Twenty-one participants received L-MTP-PE. Total serum MTP-PE declined rapidly with a terminal half-life of 2.05 ± 0.40 h. PK variability was low, with <30 % coefficient of variation in systemic exposure. Serum concentrations of IL-6, TNF-α, and CRP increased following L-MTP-PE infusion. Maximum observed increases in IL-6 and TNF-α occurred at 4 and 2 h, respectively, returning toward baseline by 8 h postdose. L-MTP-PE was generally well tolerated, with no adverse events greater than grade 3. Headache, chills, tachycardia, nausea, and pyrexia were the most frequent adverse events. L-MTP-PE infusion resulted in an increased heart rate without readily apparent QTc prolongation. Conclusions MTP-PE PK following L-MTP-PE administration were characterized by a short serum half-life and low variability. Increases in IL-6, TNF-α, and CRP and the safety profile were consistent with the immunomodulatory mechanism of action. No clinically significant effect of L-MTP-PE on cardiovascular repolarization was observed based on analysis of ECG QTc intervals. | ||
650 | 4 | |a Mifamurtide |7 (dpeaa)DE-He213 | |
650 | 4 | |a L-MTP-PE |7 (dpeaa)DE-He213 | |
650 | 4 | |a Immunomodulator |7 (dpeaa)DE-He213 | |
650 | 4 | |a Pharmacokinetics |7 (dpeaa)DE-He213 | |
650 | 4 | |a QTc |7 (dpeaa)DE-He213 | |
650 | 4 | |a ECG |7 (dpeaa)DE-He213 | |
700 | 1 | |a Kramer, William G. |4 aut | |
700 | 1 | |a Synold, Timothy W. |4 aut | |
700 | 1 | |a Goodman, Daniel B. |4 aut | |
700 | 1 | |a Sides, Evin |4 aut | |
700 | 1 | |a Oliva, Cristina |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European journal of clinical pharmacology |d Berlin : Springer, 1968 |g 68(2012), 10 vom: 30. März, Seite 1347-1355 |w (DE-627)SPR002560860 |w (DE-600)1459058-X |x 1432-1041 |7 nnns |
773 | 1 | 8 | |g volume:68 |g year:2012 |g number:10 |g day:30 |g month:03 |g pages:1347-1355 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00228-012-1262-1 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 68 |j 2012 |e 10 |b 30 |c 03 |h 1347-1355 |